n6-methyladenosine

N6-Methyladenosine is a methylated adenine residue, glycoside is an endogenous uridine product of transfer RNA degradation. It is the most prevalent internal modification of messenger RNA present in all higher eukaryotes and can modify viral RNA with antiviral activity.

N6-Methyladenosine 5'-monophosphate disodium salt is a glycogen phosphorylase b activator and an inhibitor of adenylate kinase II.

N6-Methyladenosine 5'-monophos phate triethylammonium salt (neutral 4229-50-9) is a useful organic compound for research related to life sciences and the catalog number is TNU1631.

3'-Azido-3'-deoxy-N6-methyladenosine is a Nucleoside Derivative - Azido-nucleoside, 6-Modified purine nucleoside;N-Methylated nucleoside.

3'-beta-C-Methyl-N6-methyladenosine is a Nucleoside Derivative - 3'-Modified nucleoside, N-Methylated nucleoside.

3'-Deoxy-N6-methyladenosine is a Nucleoside Derivative - 3'-Modified nucleoside, 6-Modified purine nucleoside;3'-Deoxy nucleoside.

2'-O-Methyl-N6-methyladenosine 5'-monophosphate triethylammonium salt (60091-05-6 neutral molecule) is a useful organic compound for research related to life sciences and the catalog number is TNU1630.

Nucleoside Derivatives –6-Modified purine nucleosides;N-Methylated nucleosides; Drugs and Inhibitors; Antiviral agent

Nucleoside Derivatives –6-Modified purine nucleosides; 2-Modified purine nucleosides;N-Methylated nucleosides

Nucleoside Derivatives - Fluoro-modified nucleosides, 3'-Modified nucleosides, N-Methylated nucleosides

Nucleoside Derivatives - 4'-Modified nucleosides; 6-Modified purine nucleosides; N-Methylated nucleosides

Nucleoside Derivatives - 5'-Modified nucleosides; 6-Modified purine nucleosides; N-Methylated nucleosides

Nucleoside Derivatives –Halo-nucleosides;6-Modified purine nucleosides

FB23 directly binds to FTO and selectively inhibits FTO's m6A demethylase activity. (FTO, an mRNA N6-methyladenosine (m6A) demethylase, was reported to promote leukemogenesis.)

FB23-2 is a potent and selective inhibitor of the mRNA N6-methyladenosine (m6A) demethylase FTO with an IC50 of 2.6 μM.

5'-O-DMTr-2'-O-methyl-N6-methyl adenosine 3'-CED phosphoramidite is a nucleoside phosphoramidite.

METTL3-IN-9 (compound C3) serves as an inhibitor of the RNA methyltransferase known as methyltransferase-like METTL3. This enzyme is responsible for catalyzing the N6-methyladenosine (m6A) modification of mRNA within eukaryotic cells.

ALKBH1-IN-3 is an effective inhibitor of the DNA N6-methyladenosine (6mA) demethylase ALKBH1. This compound enhances the abundance of 6mA in gastric cancer cell lines HGC27 and AGS, simultaneously inhibiting cell viability and upregulating the AMP-activated protein kinase (AMPK) signaling pathway. ALKBH1-IN-3 holds potential for use in cancer research, including studies on gastric cancer.

ALKBH5-IN-5 is a highly selective, potent and covalently binding ALKBH5 inhibitor (IC50 = 0.62 μM) that alters m6A levels on mRNA, promotes differentiation and induces apoptosis, with antitumor activity.ALKBH5 is an N6-methyladenosine (m6A) demethylase that is closely related to leukemogenesis.

Methyl piperazine-2-carboxylate (compound 4) is a potent activator of METTL3/METTL14/WTAP. It enhances the production of HIV-1p24 viral particles and increases the level of N6-methyladenosine in the viral RNA genome.

DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.

DDO-2728 is a selective pyrazolopyrimidine ALKBH5 inhibitor with an IC50 of 2.97 μM. It enhances the level of N6-methyladenosine (m6A) modification in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. Additionally, it demonstrates antitumor efficacy in MV4-11 xenograft models.

Selective FTO inhibitor (IC50 = 0.81 μM). Exhibits >30-fold selectivity for FTO over ALKBH2, 3 and 5 and >100-fold selectivity over PHD2 and JMJD2A. Increases levels of modified N6-methyladenosine (m6A) in HeLa cells in a concentration-dependent manner.

FTO-IN-8, also known as FTO-43, is an inhibitor of N6-methyladenosine demethylase FTO (fat mass- and obesity-associated protein). It exhibits an IC50 value of 5.5 μM and displays anti-cancer cell proliferative activity [1].